Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease

There is an ongoing, unmet need for effective therapies for Crohn ’s disease. Treatments for Crohn’s disease continue to evolve from the traditional biologics to novel small molecules, with targeted mechanisms directed toward pathways that are dysregulated in Crohn’s disease. There are multiple emerging mechanisms of action, including Janus kinase inhibition , Smad7 inhibition, and sphingosine-1-phosphate receptor modulators, that are administered as oral medications, and small molecules represent the next generation of therapies for Crohn’s disease.

Source: Gastroenterology Clinics of North America - August 22, 2017 Category: Gastroenterology Authors: Brigid S. Boland, S éverine Vermeire Source Type: research